1. Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivo
- Author
-
Qianran Wang, Lu Peng, Yanqiu Nie, Yanni Shu, Huajun Zhang, Zidan Song, Yufeng Li, Hengrui Hu, Liushuai Li, Xi Wang, Jia Liu, Jiang Li, Zhengli Shi, Fei Deng, Yu Guo, Yiwu Zhou, Bing Yan, Zhihong Hu, and Manli Wang
- Subjects
Virology ,Immunology ,Molecular Medicine - Abstract
Neutralizing monoclonal antibodies (mAb) are a major therapeutic strategy for the treatment of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. The continuous emergence of new SARS-CoV-2 variants worldwide has increased the urgency for the development of new mAbs. In this study, we immunized mice with the receptor-binding domain (RBD) of the SARS-CoV-2 prototypic strain (WIV04) and screened 35 RBD-specific mAbs using hybridoma technology. Results of the plaque reduction neutralization test showed that 25 of the mAbs neutralized authentic WIV04 strain infection. The 25 mAbs were divided into three categories based on the competitive enzyme-linked immunosorbent assay results. A representative mAb was selected from each category (RD4, RD10, and RD14) to determine the binding kinetics and median inhibitory concentration (IC
- Published
- 2023